الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 101 |  |  |
| | | from | 101 | | |
Abstract
Diabetes mellitus is among the oldest human disorders and the World Health Organization (W H 0) expects that the number of diabetic patients will increase to 300 million by the year 2025. For over 80 years the main therapeutic approach to insulin-dependent diabetes has been confined to treating the symptoms by insulin replacement. Because diabetes is caused by the loss of a single cell type, in recent years, cellular replacement therapy for diabetes mellitus, especially type one diabetes mellitus, has received much attention. However, there are insufficient organ donors and the recipient has to take a risk of anti-rejection therapies. Stem cells have the remarkable potential to develop into many different cell types in the body during early life and growth. In addition, in many tissues they serve as a sort of internal repair system, dividing essentially without limit to replenish other cells as long as the person or animal is still alive. When stem cell divides, each new cell has the potential either to remain a stem cell or become another type of cell with a more specialized function, such as a muscle, a red blood cell, or a brain. For this our research aims
to isolate MSCs from bone marrow and differentiate it into IPCs in vitro before transplantation to diabetic rats and discus its influence on serum glucose, serum insulin and pancreas. 50 Female white albino rats weight 165-180g under this study were classified into 4 groups as follow: 1- group (1) 10 rats donors for bone marrow for stem cells separation and culturing about 2 months under 37 c and 5%.